Introduction
Gemcitabine (2',2'-difluorodeoxycytidine; Gemzar®) is a novel pyrimidine nucleoside analog with a broad spectrum of clinical activity and a relatively mild toxicity profile. The cytotoxic activity of gemcitabine is strongly correlated with the amount of difluoro-deoxycitidine triphosphate (dFdCTP) incorporated into cellular DNA [1] . In vitro studies suggest that gemcitabine activity is schedule dependent [2, 3] . Weekly intravenous administration in heavily pretreated patients was associated with maximum tolerated doses (MTD) ranging from 790-1370 mg/m 2 /week. This schedule was selected for optimizing activity and minimizing clinical toxicity [4] . Hematological toxicity of gemcitabine given as weekly injection consists of moderate reversible neutropenia and thrombocytopenia [5, 6] . Hepatic liver dysfunction is characterized by an increase of the level of transaminase enzymes but is usually mild, non cumulative, and infrequently requires treatment discontinuation.
Other toxicities have been reported consisting of a flu-like syndrome in less than 20% of patients, edema occurring in 30% of patients, and cutaneous allergic rash [7] . Several phase II trials have investigated the safety and the efficacy of gemcitabine in combination with classical cytotoxic drugs in patients with nonsmall-cell lung, small-cell lung, breast, bladder, head and neck, ovarian, and pancreatic cancer [8] .
Vinorelbine (Navelbine®) is a semi synthetic vinca alkaloid with a potent antitumor activity related to its ability to prevent the polymerization of micro-tubules and to dissolve mitotic spindles [14] . When used at the recommended dose of 30 mg/m 2 /week, the main toxicity is a reversible grade 3-4 neutropenia occurring approximately in 20% of cycles [9] . Neurotoxicity is often mild and limited to a decrease or an abolition of the osteotendinous reflex. Paresthesia and rare paralytic ileus have also been reported with this agent. Vinorelbine has a major single-agent antitumor activity in patients with breast, lung, and digestive malignancies [10] [11] [12] . The mechanism of action of the two drugs is very different. Gemcitabine is a potent inhibitor of DNA synthesis. This inhibition is linearly correlated to intracellular concentrations of active triphosphates [13] . Mechanisms of resistance to gemcitabine have been investigated in ovarian carcinoma cell-lines. Characterization of resistant clones showed that deoxy-cytidine kinase (dCk) deficiency was the major cause of resistance. P-glycoprotein did not appear to be involved in drug resistance in this A2780 human ovarian carcinoma cell line [15] . Since mechanisms of action and drug resistance are different, and since both drugs have remarkable broad spectrum of activity, we decided to investigate the safety of the combination in a phase I clinical trial.
This phase I study was conduced to determine the doses of gemcitabine and vinorelbine in combination in patients with solid tumors refractory to classical anticancer agents. The aim of this study was to describe the toxicity, to determine the dose-limiting toxicity (DLT), and to recommend doses for future phase II trials of this combination.
Patients and methods

Eligibility
Patients with histologically proven advanced solid tumor refractory to standard treatment were eligible for this study. All patients were required to give a written inform consent according to institutional and national guidelines.
Eligibility criteria also included : 1) Karnofsky performance statuŝ 6 0 ; 2) age 18-75 years; 3) life-expectancy > 3 months (enabling the completion of at least two courses of treatment); 4) no radiotherapy within three weeks prior entering onto the study; 5) adequate bone marrow reserve: white blood cell count 3.5 x 1O 9 /1, platelets 100 x 1O 9 /I. hematocrit > 30%. adequate liver function : bilirubin <1.5 upper normal limit (UNL). alanine transaminase (ALAT) or aspartate transaminase (ASAT) < 3 UNL or < 5 UNL in the presence of liver metastasis, and normal renal function: (creatinine < 1.5 UNL); 6) no serious concomitant disease: 7) no known brain or leptomeningeal metastasis; 8) a normal calcemia: 9) no use of any investigational agent within four weeks prior the study.
Treatment
Gemcitabine was provided by Eli Lilly Inc. in vials containing 200 mg or 1 g of gemcitabine as the hydrochloride salt (expressed as free base), mannitol, and sodium acetate. Drug vials were reconstituted with normal saline to make a solution containing < 10 mg/ml.
Pierre Fabre Company provided vinorelbine in vials containing 10 mg and 50 mg. Appropriate amount of drug was diluted in normal saline solution. Gemcitabine and vinorelbine were administered intravenously weekly for two consecutive weeks (day 1 and 8), followed by a oneweek rest period. A 21-day (3 weeks) period define a cycle of therapy. Both drugs were administered as a 30-minute infusion, with vinorelbine given prior to gemcitabine, preceded by 8 mg intravenous ondansetron for prophylaxis of nausea and vomiting. The starting doses for gemcitabine and vinorelbine were 800 mg/m and 20 mg/m 2 , respectively. Starting doses were selected based on single agent phase I studies showing minimal toxicity [4, 10] ,
Follow-up
Physical examinations and laboratory studies were performed pretreatment then weekly. Routine laboratory studies included complete blood cell counts with differential white blood cell (WBC) and platelet counts, chemistry, electrolytes, blood urea nitrogen, creatinine, glucose, total protein, albumin, calcium, phosphate, magnesium, uric acid, alkaline phosphatases, total bilirubin, ALAT, ASAT, and urinalysis. An electrocardiogram was performed pretreatment. When a patient experienced a grade 3 and 4 neutropenia, the determination of hematologic parameters was recommended daily until the recovery of an ANC >2000/ul and a platelet count 5= 100,000/ul. Toxicity was assessed according Word Health Organization (WHO) criteria [16] .
Tumor measurements were performed after two courses, and patients were allowed to continue treatment until progression. Responses were evaluated following standard WHO criteria [16] , A complete response was defined as the disappearance of all known disease, maintained for four weeks. A partial response required a 50% or greater reduction in the sum of the product of the bidimensional measurements separated by at least four weeks. Disease progression was defined as greater than a 25% increase in the sum of products of measurable lesions, appearance of any new tumor lesion, or reappearance of lesions.
Procedure for dose escalation Dose limiting toxicity (DLT) was defined as: 1) any WHO grade 4 hematological toxicity; 2) WHO grade 4 nausea and vomiting despite 5-HT3-prophylaxy; 3) any other WHO grade > 3 toxicity, excluding alopecia, nausea and vomiting.
The DLT occurring after the first cycle was used for dose escalation. A minimum of three patients per group was included. If no patient in a group of 3 experienced DLT after the first dose, then the doseescalation resumes to the next higher dose level with a minimum interval of 21 days. If one patient of the group of three experienced a DLT. three more patients had to be treated at this dose level. If a DLT occurs in > 2 out of the 6 patients treated at the selected dose level, the dose escalation stopped. 
Definition of the MTD and the recommended dose
The dose level at which > 33% of patients (i.e., > 1 of 3, > 2 of 6, or > 4 of 12 patients) experienced a DLTat the first cycle defined the MTD.
The recommended dose level for phase II studies was define as the highest dose level at which ^3 3 % of patients experienced a DLT during the first cycle. Furthermore, we decided to expand the recommended dose level up to 12 patients to ensure that the doses recommended for phase II would be feasible after repeated cycles.
The doses of gemcitabine (range 800-1500 mg/m 2 ) and vinorelbine (range 20-30 mg/m 2 ) were selected prior to the study initiation as indicated in Table 3 . We decided for safety reasons that the recommended doses for the combination should not go beyond the recommended doses of single agent gemcitabine and vinorelbine. Therefore, we decided that dose level 6 would be the stopping dose level in this study if the MTD could not be reach at a lower dose-level.
With this definition, if the MTD is reached before or at dose-level 6, the recommended dose level would be a dose level below the MTD.
If the MTD is not reached at dose-level 6, then dose-level 6 would be expanded up to 12 patients and considered as the /ecommended dose for phase II if < 4 of 12 patients experienced a DLTat the first cycle.
Dose modifications based on toxicity
The treatment resumed immediately after recovery from hematological 9 9 toxicity (i.e., WBC /l). Treatment was postponed for a week if a patient did not recover from toxicity at the beginning of the next cycle. In addition, non-hematological toxicity (except alopecia and vomiting) had to return to grade 0 or 1 before resuming treatment.
In case of febrile neutropenia and thrombocytopenia associated with bleeding the doses were reduced by 25% (Table 1 ). In case of grade 4 non-hematological toxicity, the decision depended on the judgment of the investigator.
Results
Patient characteristics
Thirty-six patients with histologically documented advanced solid tumors received a total of one hundred thirty-three courses (median 3.7, range 1-17). Patient characteristics and dose levels are summarized in Table 2 .
All patients and courses were evaluable for toxicity. One episode of reversible grade 3 hepatic DLT occurs in a patient enrolled at dose level 1. No further toxicity was observed at dose level 1. One patient experience grade 4 neutropenia at dose level 2 and another at dose level 3. No DLT was observed at dose levels 4 and 5. Since the MTD was not reached at dose-level 6 in the first 6 patients, dose-level 6 was expanded up to 12 patients (Table 3) . Among those 12 patients, a DLT was observed in 3 patients during the first cycle (grade 4 hematologic toxicity in one patients, a grade 3 elevation of transaminases in a second patient, and a grade 3 flu-like syndrome in a third patient). Therefore, since 3 of 12 patients (<33%) experienced a DLTat the first cycle at dose level 6, this dose was considered as the recommended dose for phase II.
Hematologic toxicity
The hematological toxicity at each planed dose levels is summarized in Table 4 .
Neutropenia was the dose limiting toxicity. No hematological toxicity occurred at dose level 1 during the first cycle. Grade 4 neutropenia was observed in one patient at dose level 2 and another at dose level 3. No hematological toxicity was observed at dose levels 4 and 5.
A total of 48 courses were delivered at dose level 6 in a total of 12 patients. At this dose level, one patient experienced a febrile grade 4 neutropenia during the first cycle occurring at day 8 and associated with a septic shock at day 15. The patient died at day 16 despite intensive care. Two other patients experienced grade 3-4 neutropenia at dose-level 6. Among a total of 48 cycles, 5 episodes of grade 4 neutropenia (10.4%) and 6 episodes of grade 3 neutropenia (12.5%) were observed at dose level 6 (22.9% of grade 3-4 neutropenia). Neutropenia usually occurred at day 8 and lasted for a median number of five days. None of the patients treated at dose level 6 who did not presented neutropenia during cycle 1 and 2 treated developed further cumulative hematologic grade 3-4 neutropenia after repeated injections. However, patients who did experienced grade 3-4 neutropenia at the first or the second cycle had repeated hematologic toxicity during subsequent cycles.
Grade 4 thrombocytopenia was observed in one patient at dose level 3 (nadir at 20.0 x 1O 9 /1, that did not required platelet transfusion), and in one heavily pretreated patient during the second course at dose level 6. Over 133 cycles, a total of 4 grade 3 thrombocytopenia was observed (3 at dose level 3 and one at dose level 6).
One episode of grade 3 anemia was observed at dose level 1, one at dose level 3, one at dose level 4. No grade 4 anemia was observed.
Non-hematologic toxicity
Considering prophylactic treatment with 5-HT3, nausea and vomiting were infrequent and mild to moderate with only 14 episodes of grade 3 vomiting. Alopecia, stomatitis, and diarrhea were not observed.
Reversible grade 3 hepatic toxicity occurred in two patients during the first cycle at dose levels 1 and 6. This toxicity lasted for seven days and was fully reversible. It always occurred at day 15 and recovered to normal before day 21. The toxicity concerned both ASAT and ALAT without any modification of serum alkaline phosphatases or gamma glutamyl transferases. This toxicity was previously reported with gemcitabine and does not appear to be dose-related in this study. No change in serum creatinine or blood urea nitrogen was observed. No rash and no peripheral edema occurred in this schedule as previously described during phase I with gemcitabine alone.
Grade 3 flu-like syndrome was associated with grade 3 fatigue in one patient treated at dose-level 6. This event required a hospitalization for three days which led the patient to refuse further treatment. Mild flu like syndromes and fatigue were also observed at dose level 3 and 5 for doses of gemcitabine above 1000 mg/m 2 .
Tumor responses
Thirty-four patients were evaluable for tumor response. Two patients experienced a severe toxicity after the first cycle and were withdrawn from the study before tumor evaluation. Eleven patients showed tumor stabilization and received a total of fifty-eight courses (median 5.2, range 2-10) of chemotherapy. One patient with advanced mesothelioma presented a partial response that lasted for 16 weeks after 6 courses at dose level 2.
One patient with hepatic metastasis and locally advanced pancreatic adenocarcinoma, who experienced tumor progression while previously treated with a combination of 5-fluorouracil (5-FU) and cisplatin, achieved a 80% partial response after four courses then a complete response of the primary after six courses. The patient recovered normal weight and was able to start working after four months of treatment showing a clear clinical benefit from this combination. This patient is still alive with a maintained partial response under therapy one year after the beginning of the study (17 cycles).
Discussion
Both gemcitabine and vinorelbine are active drugs when given as single agents in a number of metastatic solid tumors. Therefore, we initialized a phase I dose escalation study to define the DLT and the recommended doses of gemcitabine and vinorelbine in combination.
In our study, the dose escalation proceeded up to a dose level corresponding to the recommended doses of gemcitabine and vinorelbine given as single agents. We denned that the recommended doses of gemcitabine and vinorelbine in combination delivered at day 1 and 8 every three weeks in patients previously treated with chemotherapy were 1500 and 30 mg/m 2 , respectively. The dose limiting toxicity was neutropenia. At the recommended dose, hematological toxicity was often manageable and of short duration. Since the recommendation of doses for phase II might not only rely on the acute toxicity occurring after the first cycle but shall also take into account subsequent cycles to properly determine the feasibility of the recommended schedule, we evaluated the toxicity among the 12 patients and 48 cycles given at the recommended dose. We observed a grade 3-4 neutropenia in 22.9% of the cycles including only 10.4% of grade 4 neutropenia/cycle. The hematologic toxicity often occurred during the first or the second cycle and more often occurred in heavily pretreated patients or patient previously treated with pelvic radiotherapy. No cumulative toxicity appeared in patients receiving more than two cycles of chemotherapy. In our study, one patient died of severe neutropenia associated with a septic shock. This patient had previously experienced severe hematological and cutaneous toxicity to a 5-FU-based chemotherapy. He also had previously received a pelvic irradiation. Since gemcitabine toxicity was associated with mucositis and diarrhea, we speculated a possible cross toxicity between the two drugs. We did not find any DPD deficiency. However, the ribonucleotide reductase is a common enzyme in the metabolism of 5-FU and gemcitabine. The ribonucleotide reductase enzyme has a function in the activation of 5-FU and is inhibited by gemcitabine blocking the de novo deoxyribonucleotide synthesis. We might speculate that a constitutive overexpression of this enzyme could explain an increase toxicity of 5-FU, but in this case, a decrease activity of gemcitabine would have been expected. Conversely, a down expression of the ribonucleotide reductase would decrease the clinical activity of 5-FU and increase clinical activity of gemcitabine, thereby, be responsible at least in part in the common toxicity between the two drugs.
Three phase II studies of single agent gemcitabine have been completed in patients with advanced nonsmall-cell lung carcinoma. In these trials, the starting doses of gemcitabine ranged 800-1250 mg/m 2 every four weeks. Grade 3 and 4 neutropenia occurred in 26% and 6% of patients [17] [18] [19] , respectively. In our study, the dose intensity of gemcitabine at the dose level 6 was equivalent to the dose intensity used in these phase II studies of single agent gemcitabine. Fossella et al. [6] in a recent study redefined the MTD of gemcitabine at the dose of 2800 mg/nr/week every three weeks suggesting that the MTD was initially underestimated. However, doses of gemcitabine over 3000 mg/nr/month are not yet established and were never reported to be associated with higher response rate. Importantly, in our study, vinorelbine did not increase the hematological toxicity of gemcitabine despite a high-dose intensity of 90 mg/nr/month at dose level 6.
A phase I-II study combining gemcitabine with a fixed dose of vinorelbine has been recently reported [22] . The DLT was thrombocytopenia. The recommended dose was established at 30 mg/m 2 vinorelbine combined with 1200 mg/m" gemcitabine on days 1 and 8 every three weeks. The authors observed three among four patients with dose-limiting thrombocytopenia when gemcitabine was given at the dose of 1500 mg/m 2 . Patients entering this study had non-small-cell lung cancer with good performance status and a normal bone marrow reserve at the study entry. No details were provided in the published abstract concerning previous treatments. In our study, we used the same schedule but the dose of 1500 mg/m 2 gemcitabine could be safely combined with 30 mg/m 2 vinorelbine at day 1 and 8. Another phase I study [28] combining gemcitabine and vinorelbine in patient with non-small-cell lung cancer was recently published. In this study, gemcitabine and vinorelbine were given on day 1, 8, and 15. The dose limiting toxicity was leukopenia and thrombocytopenia and the recommended doses were 20-25 mg/m 2 vinorelbine and 1000-1200 mg/m 2 gemcitabine. The dose intensity of gemcitabine in this regimen (3000-3600 mg/m 2 /cycle) correlates with the dose intensity reported in our study (3000 mg/m 2 /cycle). In our study, we observed only two episodes of grade 3-4 thrombocytopenia and no grade 3 or 4 anemia at the recommended dose. As previously described, anemia and thrombocytopenia are infrequent with vinorelbine [20] and gemcitabine used as single agents on a weekly schedule [21] . Obviously, no enhancement of the hematologic toxicity between the drugs appeared at the recommended dose in our study. Therefore, the patient selection may account for the discrepancy observed between phase I studies.
A transient hepatic toxicity was frequently observed. We observed that grade 3 elevation of transaminases lasted for seven days and returned to normal before the next cycle. Gemcitabine as single agent is known to be associated with grade 3-4 elevations of serum transaminases in approximately 10% of patients [5] [6] [7] [8] but these infrequently (0.5%) require treatment discontinuation. Vinorelbine is also infrequently associated with liver dysfunction [23] . In our study, vinorelbine did not seem to increase gemcitabine hepatic toxicity. Since this toxicity was fully reversible in all patients by day 21, we assume that the occurrence of hepatic dysfunction within 15 days after the combination does not require dose adjustment or treatment delay.
Flu-like syndromes combining fever, chills, myalgia and fatigue, occurred in a total of 10 of 85 cycles (12%) from dose levels 1-5 and in 15 of 48 cycles (31%) at the recommended dose level. The incidence of this event was not cumulative, but rather seemed to decrease with time (30% after the first cycle, 17% after the second, and 8% after the third cycle). This symptom was reported in approximately 20% of patients in phase I studies with gemcitabine given as a single agent. Fever was usually < 38.5 °C, lasted about three days. Due to a severe flu like syndrome and fatigue, one patient treated at dose level 6 discontinued treatment after the first injection of gemcitabine and we considered this event as a DLT. Gemcitabine, despite a low response rate [24] , improves disease-related symptoms and survival in pancreatic cancer [25] . No published data reported the antitumor activity of vinorelbine in pancreatic cancer [26] . While the aim of this study was not to address the efficacy of the combination, we found two objective clinical responses. Furthermore we observed tumor stabilization and clinical benefits [27] in 10 patients with either mesotheliomas (in 3 patients), bronchiolaveolar carcinoma (1 patient), thyroid carcinoma (2 patients), head and neck cancer (in 1 patient), or non-small-cell lung carcinoma (in 3 patients). At the MTD, we observed one partial response in a patient with pancreatic carcinoma associated with liver metastasis. The patient had initially a clear clinical benefit of the treatment and achieved a complete response of the primary after six cycles with a partial response (80%) of liver metastasis. One year after the beginning of treatment (17 courses), this patient finally had surgical resection (pancreatoduodenectomy-Whipple's procedure). No hepatic metastasis was found during surgery. Pathological analyses show microscopic residual carcinoma in the pancreas. The patient is still alive and disease free 18 months after the beginning of treatment.
In summary, we showed that the co-administration of gemcitabine and vinorelbine did not enhance the toxicity profile of either drug. From this study, we consider that gemcitabine and vinorelbine can safely be combined at day 1 and 8 every three weeks at the doses of 1500 and 30 mg/m 2 , respectively. The activity of the combination in a patient with pancreatic cancer resistant to a cisplatin-5-FU-based chemotherapy and in a patient with mesothelioma supports further evaluation of this regimen in patients with tumor refractory to classical antitumor agents.
